These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Hamdi Y; Soucy P; Kuchenbaeker KB; Pastinen T; Droit A; Lemaçon A; Adlard J; Aittomäki K; Andrulis IL; Arason A; Arnold N; Arun BK; Azzollini J; Bane A; Barjhoux L; Barrowdale D; Benitez J; Berthet P; Blok MJ; Bobolis K; Bonadona V; Bonanni B; Bradbury AR; Brewer C; Buecher B; Buys SS; Caligo MA; Chiquette J; Chung WK; Claes KB; Daly MB; Damiola F; Davidson R; De la Hoya M; De Leeneer K; Diez O; Ding YC; Dolcetti R; Domchek SM; Dorfling CM; Eccles D; Eeles R; Einbeigi Z; Ejlertsen B; ; Engel C; Gareth Evans D; Feliubadalo L; Foretova L; Fostira F; Foulkes WD; Fountzilas G; Friedman E; Frost D; Ganschow P; Ganz PA; Garber J; Gayther SA; ; Gerdes AM; Glendon G; Godwin AK; Goldgar DE; Greene MH; Gronwald J; Hahnen E; Hamann U; Hansen TV; Hart S; Hays JL; ; Hogervorst FB; Hulick PJ; Imyanitov EN; Isaacs C; Izatt L; Jakubowska A; James P; Janavicius R; Jensen UB; John EM; Joseph V; Just W; Kaczmarek K; Karlan BY; ; Kets CM; Kirk J; Kriege M; Laitman Y; Laurent M; Lazaro C; Leslie G; Lester J; Lesueur F; Liljegren A; Loman N; Loud JT; Manoukian S; Mariani M; Mazoyer S; McGuffog L; Meijers-Heijboer HE; Meindl A; Miller A; Montagna M; Mulligan AM; Nathanson KL; Neuhausen SL; Nevanlinna H; Nussbaum RL; Olah E; Olopade OI; Ong KR; Oosterwijk JC; Osorio A; Papi L; Park SK; Pedersen IS; Peissel B; Segura PP; Peterlongo P; Phelan CM; Radice P; Rantala J; Rappaport-Fuerhauser C; Rennert G; Richardson A; Robson M; Rodriguez GC; Rookus MA; Schmutzler RK; Sevenet N; Shah PD; Singer CF; Slavin TP; Snape K; Sokolowska J; Sønderstrup IM; Southey M; Spurdle AB; Stadler Z; Stoppa-Lyonnet D; Sukiennicki G; Sutter C; Tan Y; Tea MK; Teixeira MR; Teulé A; Teo SH; Terry MB; Thomassen M; Tihomirova L; Tischkowitz M; Tognazzo S; Toland AE; Tung N; van den Ouweland AM; van der Luijt RB; van Engelen K; van Rensburg EJ; Varon-Mateeva R; Wappenschmidt B; Wijnen JT; Rebbeck T; Chenevix-Trench G; Offit K; Couch FJ; Nord S; Easton DF; Antoniou AC; Simard J Breast Cancer Res Treat; 2017 Jan; 161(1):117-134. PubMed ID: 27796716 [TBL] [Abstract][Full Text] [Related]
27. The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Kaufman B; Laitman Y; Ziv E; Hamann U; Torres D; Lahad EL; Beeri R; Renbaum P; Jakubowska A; Lubinski J; Huzarski T; Tołoczko-Grabarek A; Jaworska K; Durda K; Sprudle AB; Chenevix-Trench G; Simard J; Easton DF; Antonis A; Szabo C; Friedman E Breast Cancer Res Treat; 2011 Apr; 126(2):521-7. PubMed ID: 20798986 [TBL] [Abstract][Full Text] [Related]
28. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778 [TBL] [Abstract][Full Text] [Related]
29. Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers. Milne RL; Antoniou AC Ann Oncol; 2011 Jan; 22 Suppl 1():i11-7. PubMed ID: 21285145 [TBL] [Abstract][Full Text] [Related]
30. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Foulkes WD; Metcalfe K; Sun P; Hanna WM; Lynch HT; Ghadirian P; Tung N; Olopade OI; Weber BL; McLennan J; Olivotto IA; Bégin LR; Narod SA Clin Cancer Res; 2004 Mar; 10(6):2029-34. PubMed ID: 15041722 [TBL] [Abstract][Full Text] [Related]
31. Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country. Yip CH; Taib NA; Choo WY; Rampal S; Thong MK; Teo SH World J Surg; 2009 Oct; 33(10):2077-81. PubMed ID: 19649760 [TBL] [Abstract][Full Text] [Related]
33. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414 [TBL] [Abstract][Full Text] [Related]
34. Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry. Casey MJ; Bewtra C; Lynch HT; Snyder C; Stacy M; Watson P Fam Cancer; 2013 Dec; 12(4):719-40. PubMed ID: 23666231 [TBL] [Abstract][Full Text] [Related]
35. Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers. Park JS; Lee ST; Han JW; Kim TI; Nam EJ; Park HS Clin Breast Cancer; 2018 Oct; 18(5):362-373.e1. PubMed ID: 29673794 [TBL] [Abstract][Full Text] [Related]
36. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections. Fountzilas E; Konstantopoulou I; Vagena A; Apostolou P; Papadimitriou C; Christodoulou C; Tryfonopoulos D; Manousou K; Delimitsou A; Papamentzelopoulou M; Fountzilas G; Yannoukakos D; Fostira F Clin Breast Cancer; 2020 Apr; 20(2):152-159. PubMed ID: 31980407 [TBL] [Abstract][Full Text] [Related]
37. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832 [TBL] [Abstract][Full Text] [Related]
38. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers. Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051 [TBL] [Abstract][Full Text] [Related]
39. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502 [TBL] [Abstract][Full Text] [Related]
40. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A; Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]